Korea’s Hanmi Ships Combination Amosartan To Merck For Global Sales
This article was originally published in PharmAsia News
Executive Summary
Hanmi recently concluded the first supply agreement of a Korean firm's combination product with a multinational company.
You may also be interested in...
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.
S Korean president pushes pharma deals in Middle East
While the South Korean pharma sector is ultimately targeting US and European markets in its longer-term expansion drive, it is for now trying to build up wider relations with Middle East countries with a little top-level political help.